Quick Answer
PMV Pharmaceuticals, Inc. reported Total Assets of $116.56 million for the year ending 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -39.1% in Total Assets from 2024 to 2025.
- This data is from PMV Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $374.45 million | Q1 2021: $354.39 million | Q2 2021: $355.91 million | Q3 2021: $344.18 million | Q1 2022: $315.01 million | Q2 2022: $300.56 million | Q3 2022: $284.98 million | Q1 2023: $253.96 million | Q2 2023: $242.22 million | Q3 2023: $261.03 million | Q1 2024: $236.88 million | Q2 2024: $237.54 million | Q3 2024: $223.50 million | Q1 2025: $170.61 million | Q2 2025: $152.86 million | Q3 2025: $133.84 million.
- Over the full 7 years of available data (2019 to 2025), PMV Pharmaceuticals, Inc.'s Total Assets has grown by 13.1%.
- Historical annual values: Fiscal year 2025: $116.56 million | Fiscal year 2024: $191.29 million | Fiscal year 2023: $252.15 million | Fiscal year 2022: $270.31 million | Fiscal year 2021: $331.57 million | Fiscal year 2020: $365.53 million | Fiscal year 2019: $103.03 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: